Advisory Research’s Sage Therapeutics SAGE Stock Holding History

Advisory Research’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,975	Closed	-$476K	–	465
2017 Q2	$476K	Buy	+5,975	New	+$432K	0.01%	368

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Advisory Research's SAGE Position: Q3 2017 in Review

Advisory Research sold out of Sage Therapeutics (SAGE) in Q3 2017, closing a stake of 5,975 shares — an estimated $476K sold.

Advisory Research first reported a position in SAGE in Q2 2017 and held it in 1 quarter. The position peaked at $476K in Q2 2017. 174 funds tracked by Wall St. Rank hold SAGE as of Q3 2017.

Advisory Research reported no remaining Sage Therapeutics position as of Q3 2017 after selling out during the quarter.
Advisory Research sold 5,975 Sage Therapeutics shares in Q3 2017, an estimated $476K.
Advisory Research first reported a position in Sage Therapeutics in Q2 2017 and held it in 1 quarter.
Advisory Research's Sage Therapeutics position peaked at $476K in Q2 2017.
174 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2017.

Based on Advisory Research's 13F filing for Q3 2017, filed 14 Nov 2017.